Адаптация персонала организации на примере сети кафе «Пельмени Project»

Объектом исследования является–система адаптации персонала в кафе «Пельмени Project» и разработка путей ее совершенствования. Предметом исследования является – система адаптации персонала. Цель работы– оценка системы адаптации и разработка методов ее совершенствования в кафе «Пельмени Project». В процессе исследования проводился комплексный опрос. В результате исследования были разработаны рекомендации по улучшению системы адаптации персоналом в кафе «Пельмени Project». Степень внедрения:система адаптации молодых сотрудников в кафе «Пельмени Project» находится на хорошем уровне, проводятся различные мероприятия для благоприятной адаптации на работе, несмотря на это, все равно существует ряд недоработок в этой области, подтверждением тому является текучка кадров и неудовлетворенность новых сотрудников.The object of this study is to adapt the system-staff in the cafe "Dumplings Project» and to develop ways to improve it. The subject issledovaniyayavlyaetsya - personnel system adaptation. The purpose work- evaluation system to adapt and develop methods to improve it in the cafe "Dumplings Project». The study conducted a comprehensive survey. The study developed recommendations to improve the personnel system to adapt to the cafe "Dumplings Project». Degree of implementation: adapting the system of young staff in the cafe "Dumplings Project» is at a good level, hosts a variety of supportive measures for adaptation to work, in spite of this, all still there are some shortcomings in this area, confirming that is staff turnover and dissatisfaction with the new employees

PROLONGED MUSCULAR FLACCIDITY IN STROKE PATIENTS IS ASSOCIATED WITH CROSSED CEREBELLAR DIASCHISIS

In order to evaluate whether hypotonia could be the clinical expression of crossed cerebellar diaschisis (CCD), we studied the occurrence and severity of CCD in two groups of hemiparetic stroke patients presenting either with prolonged muscular flaccidity (PMF, n = 14) or with muscular spasticity (MSp, n = 13) over the affected hemisoma. CCD was more frequent and severe in hypotonic than in spastic patients. Neither the time elapsed from the stroke nor the volume of the lesion was significantly different between patients with PMF and those with MSp. The two groups of patients showed different motor deficit scores, but motor deficit severity and CCD did not correlate. We concluded that the persistence of CCD after stroke may be associated with PMF, emphasizing the link between functional cerebellar impairment and muscular hypotonia

QUANTITATIVE ASSESSMENT OF CEREBRAL BLOOD-FLOW IN PARTIAL EPILEPSY USING XE-133 INHALATION AND SPECT

The Xe-133 inhalation method was used to study rCBF in 12 patients with partial epilepsy during the interictal phase. SPECT images evidenced a focal CBF defect in 1 0 out of 12 patients, while quantitative analysis showed CBF abnormalities in all the patients. The focal CBF defect corresponded to the site of EEG abnormalities in nine patients. Additional low-flow areas beyond the EEG focus were found. Five patients presented a significant CBF decrease in the cerebellar hemisphere contralateral to the EEG focus. In five patients with unilateral EEG abnormalities, a CBF reduction was found in the contralateral cerebral hemisphere, mirror to the EEG focus. Finally, a widespread CBF decrease involving one or both cerebral hemispheres was observed in seven patients. Global and rCBF values were not correlated with age, duration of disease, frequency of seizures, secondary generalization, or specific therapy. SPECT may be useful in evaluating EEG epileptic foci, and quantitative SPECT allows the detection of functional effects of the epileptic focus on anatomically connected remote areas, probably due to the decrease of afferent inputs (diaschisis phenomenon)

Supplementary Material for: A Study of Clinical Features and Risk Factors of Self-Referring Emergency Department Headache Patients: A Comparison with Headache Center Outpatients

Background: Nonlife-threatening headaches account for 3% of emergency department (ED) admissions, with social and economic negative consequences. We aim to investigate clinical features and risk factors of nonlife-threatening headache patients referring to ED versus those referring to headache outpatient clinics. Methods: During 6 months, we promptly reevaluated in our headache unit (HU) patients discharged from ED. We compared the clinical characteristics of patients who referred to ED with those of HU outpatients visited in the same time interval. Discriminant Function Analysis and Correspondence Analysis were used to determine risk factors for ED referral. Results: We recruited 49 post-ED patients and 126 outpatients. The main reasons for ED admission were poor response to acute treatment and aura-related symptoms. Headache diagnoses made in ED were generally not confirmed later (overall concordance of 47%), except for cluster headache (CH) and migraine with aura (MA). ED patients complained higher headache intensity, longer duration, and prolonged aura compared to outpatients. Aura was the main risk factor associated with ED admission on statistical models, while less prominent risk factors were sex, age, and years from migraine onset. Conclusions: ED patients presented a more severe headache clinical phenotype compared with outpatients. Headache diagnosis remains difficult in the emergency setting and is more easily achieved for the headache forms with standout features, such as MA or CH. According to statistical models, the aura is the most important risk factor for ED admissions

Supplementary Material for: A Propensity Score Matching Study on the Effect of OnabotulinumtoxinA Alone versus Short-Term Psychodynamic Psychotherapy Plus Drug-of-Choice as Preventive Therapy in Chronic Migraine: Effects and Predictive Factors

Objective: The objective of this study was to test the superiority of multidisciplinary approach, that is, Short-Term Psychodynamic Psychotherapy (STPP) plus drug of choice, versus monotherapy, that is, OnabotulinumtoxinA (OnaBoNT-A). Method: We consecutively recorded data from chronic migraine (CM) patients, with or without medication overuse headache (MOH), who underwent STPP or OnaBoNT-A, with a 3-month follow-up schedule. Headache days and analgesics intake were monitored as primary outcome measures. Propensity score matching (PSM) was used to eliminate discrepancies between groups. Discriminant function analysis (DFA) was used to pinpoint predictive factors associated with the clinical response. Results: 96 patients with CM (64% with MOH) were treated with STPP and 54 (59% with MOH) with OnaBoNT-A. At baseline, OnaBoNT-A patients had more failed preventive therapies, more years of illness and chronicity, and were older; STPP patients were more depressed and had a higher HIT-6. Both STPP and OnaBoNT-A patients showed a significant reduction of headache days (STPP: −14 vs. OnaBoNT-A:−14.3) and analgesics intake (STPP: −12,3 vs. OnaBoNT-A −13.5 pills/month), respectively. MOH diminished more in STPP, adherence was higher in OnaBoNT-A. Results were confirmed after PSM balancing of the groups for those variables that resulted as different (but age). Conclusion: OnaBoNT-A monotherapy produced similar results to psychotherapy plus medication, after correcting for baseline differences

BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

Introduction: Fucosyl-GM 1 is a monosialoganglioside with limited expression in healthy tissues and high expression on SCLC cells. BMS-9860 12 is a nonfucosylated, first-in-class, fully human immunoglobulin G1 monoclonal antibody that binds to fucosyl-GM1. Methods: CA001-030 is a phase 1/2, first-in-human study of BMS-986012 as monotherapy or in combination with nivolumab for adults with relapsed or refractory SCLC. Safety is the primary end point. Additional end points include objective response rate, duration of response, progression-free survival, pharmacokinetics, and overall survival.Results: Patients (BMS-986012 monotherapy, n = 77; BMS986012 thorn nivolumab, n = 29) were predominantly of male sex (58%), 63 years old (mean), current or past tobacco users (97%), and treated previously with first-line systemic therapy (99%). The most common treatment-related adverse event was pruritus (n = 95 [90%]). Grade 4 treatment-related adverse events were reported in 2% (n = 2) of patients. The objective response rate (95% confidence interval [CI]) was higher with BMS-986012 plus nivolumab (38% [20.7%-57.7%]) than with monotherapy (4% [0.8%- 11.0%]). Median (95% CI) duration of response with BMS986012 plus nivolumab was 26.4 (4.4-not reached) months. Progression-free survival (95% CI) at 24 weeks with monotherapy and BMS-986012 plus nivolumab was 12.2% (6.0%-20.7%) and 39.3% (21.7%-56.5%), respectively. The pharmacokinetics profile of monotherapy and BMS-986012 plus nivolumab suggested dose proportionality across the tested dose range. Median overall survival (95% CI) with monotherapy and BMS-986012 plus nivolumab was 5.4 (4.0-7.3) and 18.7 (8.2-37.3) months, respectively.Conclusions: BMS-986012 in combination with nivolumab represents a well-tolerated, potential new therapy for relapsed or refractory SCLC. BMS-986012 is currently being explored in combination with carboplatin, etoposide, and nivolumab as a first-line therapy in extensive-stage SCLC (NCT04702880).(c) 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N